Physician profile
Gregory Scimeca
NPI 1730285651
$7,583.19
in general payments reported to CMS, 2019-2025
28 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $607 · 2021: $756 · 2022: $770 · 2023: $1,248 · 2024: $1,140 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,672.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,216.06 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Merz North America, INC. | $802.91 | 2020-2023 | Xeomin |
| Abbvie INC. | $758.58 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Amgen INC. | $425.71 | 2024-2025 | Tepezza |
| Allergan, INC. | $413.22 | 2019-2022 | |
| Ocular Therapeutix, INC. | $336.51 | 2019-2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $286.81 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $203.04 | 2020-2025 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $169.58 | 2022-2024 | Envista Mx60 Iol, Vyzulta, Lotemax Sm |
| Sun Pharmaceutical Industries INC. | $141.22 | 2019-2025 | Cequa |
| Rxsight INC | $132.25 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Tarsus Pharmaceuticals, INC. | $128.38 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $72.83 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $71.21 | 2022-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $64.76 | 2022-2024 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $45.09 | 2019-2021 | |
| Revance Therapeutics, INC. | $44.15 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $37.70 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $36.32 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.48 | 2019-2021 | |
| Coherus Oncology, INC. | $29.74 | 2023 | |
| Ivantis, INC | $25.45 | 2019 | |
| Sight Sciences, INC. | $22.78 | 2025 | Omni Surgical System |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $19.26 | 2021 | |
| Ani Pharmaceuticals, INC. | $17.99 | 2025 | Purified Cortrophin Gel |
| Thea Pharma INC. | $13.92 | 2024 | Iyuzeh |
| Shire North American Group INC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Scimeca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.